BitFuFu Recaps its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
Singapore, Sept. 30, 2024 (GLOBE NEWSWIRE) — BitFuFu, Inc. (NASDAQ: FUFU, FUFU.WS) (“BitFuFu” or the “Company”) a fast-growing digital asset […]
Medallion Bank Announces Fintech Strategic Partnership With Kashable
SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) — Medallion Bank (Nasdaq: MBNKP), an FDIC-insured bank specializing in consumer loans […]
36Kr Further Expands Global Reach, Bringing Awareness of China’s Economy Worldwide
BEIJING, Sept. 30, 2024 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company”) (Nasdaq: KRKR), a prominent brand and […]
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) […]
Stellantis Updates 2024 Financial Guidance
Stellantis Updates 2024 Financial Guidance AMSTERDAM, September 30, 2024 – Stellantis N.V. today revised its 2024 financial guidance, reflecting decisions […]
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory […]
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing […]
NIO Announces RMB3.3 Billion Investment in NIO China from Strategic Investors
SHANGHAI, Sept. 29, 2024 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a […]
Digicann Ventures Signs Definitive Agreement for Proposed RTO Transaction with 3Win Corp.
/ Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, […]
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Updated Phase 1 data presented at ESH-iCMLf 26thAnnual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 […]
